DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
2020
[no abstract - showing first paragraph of article] Sodium-glucose co-transporter-2 (SGLT2) inhibitors are relatively new class of antihyperglycemic medication that is well established in the management of type 2 diabetes mellitus (DM) . It has a unique mechanism of action that targets the kidneys through inhibiting 90% of glucose reabsorption.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
12
References
0
Citations
NaN
KQI